Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

Symptomatic Bronchiectasis Clinical Trial

Status Not yet recruiting

Clinical Trial Summary

There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bronchiectasis
• Symptomatic Bronchiectasis

• NCT number: NCT01580748
• Study type: Interventional
• Source: Seoul National University Bundang Hospital
• Contact: Choon-Taek Lee, M.D., Ph.D.
• Phone: +82-31-787-7002
• Email: ctlee@snubh.org
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 2012
• Completion date: January 2013